DAMARIS ARAGON: Open Payments
NPI 1093138364 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,581 in 15 payments from 9 companies in 2025. Trend: 2023 $609 · 2024 $895 · 2025 $1,581
Food & beverage: $1,581
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $516 |
| Janssen Pharmaceuticals, Inc | 3 | $384 |
| Novo Nordisk Inc | 1 | $125 |
| ABBVIE INC. | 1 | $125 |
| E.R. Squibb & Sons, L.L.C. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $122 |
| Dexcom, Inc. | 1 | $93 |
| Lilly USA, LLC | 1 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $31 |
Products named: INGREZZA, INVEGA SUSTENNA, SPRAVATO, Wegovy, VRAYLAR, COBENFY, Auvelity, Dexcom G6 Transmitter.
Industry payments across WA — which companies pay providers there.
